Ascentage Pharma Group International (AAPG)vsJohnson & Johnson (JNJ)
AAPG
Ascentage Pharma Group International
$15.43
+1.98%
HEALTHCARE · Cap: $1.40B
JNJ
Johnson & Johnson
$276.22
+1.43%
HEALTHCARE · Cap: $657.68B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 15357% more annual revenue ($99.33B vs $642.63M). JNJ leads profitability with a 16.2% profit margin vs -228.5%. JNJ earns a higher WallStSmart Score of 54/100 (C-).
AAPG
Avoid25
out of 100
Grade: F
JNJ
Buy54
out of 100
Grade: C-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 29.3% year-over-year
Mega-cap, among the largest globally
Strong operational efficiency at 25.7%
Generating 6.4B in free cash flow
Areas to Watch
Trading at 17.3x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Trading at 8.2x book value
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : AAPG
The strongest argument for AAPG centers on Revenue Growth. Revenue growth of 29.3% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.7%.
Bear Case : AAPG
The primary concerns for AAPG are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 3.76 is elevated, increasing financial risk.
Bear Case : JNJ
The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 41.5x leaves little room for execution misses.
Key Dynamics to Monitor
AAPG profiles as a growth stock while JNJ is a mature play — different risk/reward profiles.
AAPG carries more volatility with a beta of 0.66 — expect wider price swings.
AAPG is growing revenue faster at 29.3% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (54/100 vs 25/100), backed by strong 16.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ascentage Pharma Group International
HEALTHCARE · BIOTECHNOLOGY · USA
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company is headquartered in Suzhou, China.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?